Study identifier:RO-2455-402-KR
ClinicalTrials.gov identifier:NCT02068456
EudraCT identifier:N/A
CTIS identifier:N/A
Post Marketing Surveillance of Roflumilast in Korea
Chronic Obstructive Pulmonary Disease
-
No
Roflumilast
All
1837
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jun 2017 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Roflumilast Roflumilast will be administered according to the prescribing information of the approved Korean label. | Drug: Roflumilast N/A Other Name: Daxas, Daliresp |